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Abstract
We used the State Inpatient Databases from the United States Agency for Healthcare Research and Quality to provide state-
specific age-adjusted blastomycosis-associated hospitalization incidence throughout the entire United States. Among the
46 states studied, states within the Mississippi and Ohio River valleys had the highest age-adjusted hospitalization
incidence. Specifically, Wisconsin had the highest age-adjusted hospitalization incidence (2.9 hospitalizations per 100,000
person-years). Trends were studied in the five highest hospitalization incidence states. From 2000 to 2011, blastomycosis-
associated hospitalizations increased significantly in Illinois and Kentucky with an average annual increase of 4.4% and 8.4%,
respectively. Trends varied significantly by state. Overall, 64% of blastomycosis-associated hospitalizations were among men
and the median age at hospitalization was 53 years. This analysis provides a complete epidemiologic description of
blastomycosis-associated hospitalizations throughout the endemic area in the United States.
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Introduction
Blastomyces dermatitidis and the newly described Blastomyces
gilchristi [1], dimorphic fungi, are capable of causing blastomy-
cosis infection among humans, dogs, and other mammals. The
primary route of infection is through inhalation of fungal conidia
[2]. Severity of infection in humans can vary greatly with the most
severe cases resulting in death. The epidemiologic features are
poorly understood as the organism is difficult to culture from the
environment [3] and disease reporting is only mandatory in
limited states within the endemic area (AR, WI, MN, MS, LA,
MI). Illinois ended mandatory reporting in 2008 [4,5]. The
organism exists in areas surrounding the Ohio and Mississippi
River Valleys and the Great Lakes, and southern parts of Canada
[5–8]. The area of the endemic region is substantially greater than
that of the six US states currently with mandatory reporting.
Diagnosis is most accurately achieved through culture from a
clinical specimen and initial results may be obtained as early as
after five days of incubation if clinical suspicion is high [9].
However, final confirmation by culture may take up to 30 days [9].
Serological diagnosis is also possible but some tests are limited by
low sensitivity and a high degree of cross reactivity, especially with
histoplasmosis [9–11]. This is a particular problem given the
overlap in endemic regions for these two organisms [8]. Unlike
other mycoses, blastomycosis is only rarely considered an
opportunistic infection [12]. Diagnostic delays can increase
morbidity and mortality [2].
Blastomycosis occurs sporadically and in outbreaks. Outbreaks
have been reported in multiple states with and without mandatory
reporting [7,13–16]. A recent large outbreak in Wisconsin during
2010 [13] highlighted the need for an updated epidemiologic
assessment of this disease. Additionally, other reports throughout
the endemic area are either outdated [17–19], describe local areas
[14,20,21], specific populations [8] or outbreaks only [13,22,23].
Some previous epidemiologic reports suggest the possibility of
an increasing incidence of blastomycosis cases [2,5,13,24].
Additionally, recently reported incidences are frequently higher
than those reported in previous decades for the same geographic
area [8,17–19,25]. However, to our knowledge, no studies have
assessed the possibility of an increasing trend in multiple states in
the endemic area.
An updated and comprehensive description of national
incidence and trends for blastomycosis is essential for improving
the public health response to blastomycosis and highlighting
geographic regions where blastomycosis should be considered in a
differential diagnosis for patients that resided or traveled to these
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areas. This study uses the State Inpatient Database from the US
Agency for Healthcare Research and Quality to provide updated
and nationally representative data on blastomycosis epidemiology.
Methods
We used the intramural State Inpatient Database (SID) from the
US Agency for Healthcare Research and Quality (AHRQ),
through an established collaborative effort, to describe age-
adjusted state-specific blastomycosis-associated hospitalization
incidence and trends. The AHRQ SID are produced as part of
the Healthcare Cost and Utilization Project (HCUP) and include
inpatient records from community hospitals and some non-
community hosptials in each participating state [26]. According
to the American Hospital Association, community hospitals make
up 87% of all US registered hospitals and 95% of total US
admissions [27]. They include nonfederal, short-term general,
academic and teaching hospitals [27]. Hospitalization records
were identified and extracted from the AHRQ SID database using
the International Classification of Diseases, 9th Revision, Clinical
Modification codes (ICD-9-CM). A blastomycosis-associated
hospitalization was defined as a hospital admission with any
(primary or secondary) diagnosis of blastomycosis (ICD-9-CM:
116.0 and 116). For comparison, we also collected all records with
an ICD-9-CM code for histoplasmosis (115.xx). For each
hospitalization, we collected age, race, sex, state of hospitalization,
patient state of residence and ICD-9-CM diagnostic codes for
concurrent conditions. We extracted Current Procedural Termi-
nology (CPT) codes for a subset of states in the endemic area to
provide information regarding the diagnostic practices for
blastomycosis in these states.
We included hospitalization records for all states with at least
partial participation (at least one year) in the intramural SID from
2007 to 2011 for calculating blastomycosis-associated hospitaliza-
tion incidence; 46 states were included in this analysis (Table 1),
representing 97% of the total US population in 2010. Further, to
assess trends, we extracted hospitalization records starting in 2000
or the most recent years available for the five states identified as
having the highest hospitalization incidence.
State-specific hospitalization incidence was calculated as the
average annual number of blastomycosis-associated hospitaliza-
tions in the state divided by total person-years for that state in
2010. The 2010 state-specific census data was used to approximate
the total person-years contributed by each state in 2010. The state-
specific incidence was age adjusted to the 2010 United States
population using the direct method of standardization as described
by Woodward [28]. Because of the endemic and geographically
focal nature of blastomycosis, we did not report an overall US
hospitalization incidence and instead report only state-specific
hospitalization incidence. We also calculated state-specific hospi-
talization rates using total number of hospitalizations in each state
in 2010 as the denominator to assess potential bias.
Poisson regression was used to assess significance of trends (p,
0.05). We used state-specific annual hospitalization incidence for
this analysis. We accounted for underdispersion by scaling the
standard errors using the Pearson Chi2 dispersion statistic. The
Pearson Chi2 statistic was used to assess model fit. We assessed the
potential for effect modification between year and state by using
an interaction term.
All analyses were performed using SAS version 9.3 (SAS
Institute Inc., Cary, NC).
This study was considered as not human subjects research by
the National Institutes of Health Office of Human Subjects
Research.
Results
We identified 4688 total hospitalizations for blastomycosis for all
states and all years in our study. The majority of the blastomycosis
hospitalizations were for males (64%) and the median age at
admission was 53 years. The patient demographic variable for
race was available for 2959 (63%) hospitalizations. Of these
hospitalizations with patient race information, 2038 (69%) were
identified as white, 473 (16%) black, 211 (7%) Hispanic, 89 (3%)
Asian or Pacific Islander, 40 (1%) Native American and 108 (4%)
were identified as other. The majority (92%) of all blastomycosis-
associated hosptailizations were for patients residing within the
state in which they were hospitalized.
Blastomycosis-associated hospitalizations were most frequent in
the states within the Mississippi and Ohio River valleys, with the
exception of Minnesota, Iowa and Vermont (Figures 1 and 2). The
state-specific age-adjusted hospitalization incidence ranged from
2.9 per 100,000 person-years in Wisconsin to less than 0.05 per
100,000 person-years in some Western and Northeastern states.
Wisconsin, Illinois, Tennessee, Kentucky and Arkansas had the
highest hospitalization incidence among the 46 states in our
analysis, listed in order of incidence. When using total hospital-
izations as the denominator, the states with the highest rates were
Wisconsin, Illinois, Vermont, Tennessee and Minnesota. Although
the absolute values differed, the overall pattern was similar when
using either the 2010 census population or total hospitalizations as
the denominator (Figure 2).
Of the 4688 hospitalizations for blastomycosis, only 247 (5.2%)
had a concurrent diagnosis of HIV/AIDS or a primary immune
deficiency (ICD-9-CM: 042, 279.xx). In contrast, more than 20%
of histoplasmosis-associated hospitalizations had a concurrent
diagnosis of HIV/AIDS or primary immune deficiency. Within
the endemic area, CPT codes were only available for five states
and coding within these states was incomplete; 79% of blastomy-
cosis-associated hospitalizations were missing all CPT code
Table 1. Years and states included in analysis.
States Years included in analysis
AZ, AR, CA, CO, CT, FL, GA, HI, IL, IN, IA, KS, KY, ME, MD, MA, MI, MN, MO, NE, NV, NH, NJ,





DE, ND, ID, AL, DC Not included
doi:10.1371/journal.pone.0105466.t001
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information in at least one state. Thus, CPT codes were not
reliable and were not included in the analysis.
We assessed the possibility of an increasing trend in the
incidence of blastomycosis-associated hospitalizations by state for
the five highest-incidence states. Illinois and Kentucky were found
to have an increasing incidence of hospitalizations during the
period of 2000 to 2011, with an average annual percentage change
of 4.4% (95% CI: 1.8, 7.0) and 8.4% (95% CI: 3.9, 13.1) per year,
respectively (Figure 3a). The 2000–2011 annual percentage
changes in Wisconsin and Tennessee were not significant (WI:
2.3%, 95% CI: 25.4, 5.3; TN: 21.4%, 95% CI: 23.2, 0.53).
Arkansas trend data was only available from 2004–2011 and
annual percentage change during this period was also not
significant (27.2%, 95% CI: 215.2, 1.6) (Figure 3b). In the
model with all states, the interaction term for state and year was
found to be significant, indicating the presence of effect
modification; trends varied among states.
Discussion
In this report we update the epidemiology of blastomycosis
hospitalizations in the United States. With respect to demographic
features of patients with identified hospitalizations, 64% of
hospitalizations were for male patients, similar to reports from
prior studies of blastomycosis in an outpatient population [14,20]
and higher than what was reported for blastomycosis hospitaliza-
tions by Chu et al (58%) [29]. Differences in the male to female
ratio may be related to the proportion of pulmonary and extra
pulmonary cases with a higher proportion of women having
pulmonary disease [30,31]. The median age that we report is
similar to previous reports in the outpatient population [20,29].
The racial distribution that we observed was similar to that
observed for the adult population described by Chu et al [29].
Only a small percentage (8%) of hospitalizations included patients
residing outside of the state of hospitalization. However, we were
not able to account for patients that may have traveled to an
endemic area prior to their hospitalization.
We found that the current geographic distribution of hospital-
ization incidence is similar to what has been previously described for
the endemic area of Blastomyces dermatitidis, with the highest
incidence of blastomycosis-hospitalizations found in the states
within the Mississippi and Ohio River valleys. We found a high
incidence of blastomycosis-associated hospitalizations in some areas
where blastomycosis is not a reportable disease; three of the five
highest incidence states do not currently require blastomycosis
reporting (TN, KY and IL). Our state-specific average annual
incidences of hospitalizations were comparable to previous
incidence reports for most states although some differences should
be noted. Specifically, the average annual hospitalization incidence
that we identified for Wisconsin (2.9 per 100,000 person-years) was
higher than the average annual incidence for Wisconsin identified
from 1986–1995 in a 1996 MMWR article (1.4 per 100,000 person-
years) [19]. This increased incidence may be the result of our
inclusion of a large outbreak in 2010. It could also indicate an
Figure 1. Map of age-adjusted blastomycosis-associated hospitalization incidence in the United States.
doi:10.1371/journal.pone.0105466.g001
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Figure 2. Blastomycosis-associated hospitalization incidence and rate of blastomycosis hospitalizations per all-cause
hospitalization.
doi:10.1371/journal.pone.0105466.g002
Figure 3. Trends in blastomycosis hospitalization incidence among states with a significant annual percentage change (A) and
states with no significant annual percentage change (B).
doi:10.1371/journal.pone.0105466.g003
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increasing trend as our hospitalization incidence was within the
range reported from a Medicare population from 1999–2008 [8]. In
Illinois, we found an incidence slightly higher than what was
reported for cases from the Illinois Department of Health records
[5] but within the range reported from a Medicare population [8].
Blastomycosis incidence for Arkansas among persons $65 years was
discussed in detail through letters to the editor in the journal
Emerging Infectious Diseases [25,32]. Our hospitalization inci-
dence is slightly higher than the reported incidence rates among the
elderly and lower than an incidence provided for all age groups [25]
as well as an incidence reported in a separate report from 1970 [17].
In contrast, our hospitalization incidence for Kentucky was higher
than the report from 1970, suggesting a changing epidemiology by
state [17]. Unfortunately we were unable to include Alabama as this
state does not participate in the AHRQ SID because it does not
collect statewide discharge data.
We found the hospitalization incidence in Vermont to be
among the ten highest state-specific hospitalization incidence rates
despite having an average of less than 10 blastomycosis-
hospitalizations per year. The blastomycosis endemic area
stretches into areas proximal to northwestern Vermont, where
much of Vermont’s population resides and locally acquired disease
has been documented [33]. However, instability of our incidence
rates may be an issue in areas of the United States with low
numbers of hospitalizations, such as Vermont. Vermont has the
lowest total population besides Wyoming and District of Colum-
bia. As such, this estimate is most likely a reflection of instability
due to low numbers as reflected by a wide 95% confidence interval
around the estimate (0.81 (95% CI: 0.13, 1.48)).
We used the total state population for the denominator for the
majority of our analysis. However, we also calculated state-specific
blastomycosis-associated hospitalizations per 100,000 total hospi-
talizations. Not surprisingly, the absolute estimates were different
using this methodology. However, the overall relative pattern of
values was similar between the two different methodologies. This
suggests that differences in demographic patterns among all
hospitalizations are not contributing bias to the calculation of
mean blastomycosis-associated hospitalization incidence when
using the state population as the denominator.
The possibility of an increasing trend was confirmed for the
period of 2000–2011 for two (IL and KY) of the five states with the
highest incidence of hospitalization. There was an increasing trend
in Wisconsin but it was not statistically significant. No increasing
trends were observed for Tennessee or Arkansas. We had fewer
years of historical data available for Arkansas and a longer time
period may have provided a different result. Effect modification
between state and year was observed, indicating different temporal
patterns for these states. This observation suggests that different
factors may affect either blastomycosis infections [34,35], hospi-
talizations or both in different geographic areas. Possible reasons
for this increase may include increasing awareness, changing
environmental factors, or an increase in disease incidence.
Only 5% of the blastomycosis-associated hospitalizations that
we identified had a concurrent diagnosis of HIV/AIDS or other
primary immune deficiency, indicating a minimal role of
blastomycosis as an opportunistic infection as is supported by
the literature [12,36,37]. In contrast, for another endemic mycosis,
histoplasmosis, over 20% of histoplasmosis-associated hospitaliza-
tions had a concurrent diagnosis of HIV/AIDS or a primary
immune deficiency, consistent with increased risk of chronic
pulmonary and disseminated histoplasmosis infections among
immunocompromised individuals [12]. This difference between
blastomycosis-associated and histoplasmosis-associated hospital-
izations suggests minimal misdiagnosis of histoplasmosis as
blastomycosis in the hospitalizations in our analysis.
Some limitations should be considered when interpreting our
findings. First, our data describe hospitalizations and not incident
cases of blastomycosis. We were not able to identify the frequency
of readmissions and may be overestimating the true incidence of
blastomycosis hospitalized patients if an individual is hospitalized
more than once for the same illness. The AHRQ SID provides
readmission data but this is limited to fewer states and years.
Additionally, when comparing publically available annual state
case reports (available from state websites) to AHRQ SID
hospitalization counts (available from HCUPnet [38]), we found
higher counts of hospitalizations as compared to reported cases.
This may also indicate underreporting of the disease. Although the
absolute numbers of case counts and hospitalization counts
differed, differences between years within these states and
differences between states followed similar patterns; states with
the highest hospitalization counts also had the highest case reports
and within states, years with the highest hospitalization counts also
had the highest case reports. Our estimates best represent the
incidence of blastomycosis hospitalizations and using these results
as estimates of case incidence should be avoided. Despite this
limitation, our data are valuable for describing overall patterns of
blastomycosis throughout the United States, identifying states with
high burdens of disease and describing annual changes in
hospitalizations and burden of disease.
A second limitation related to our use of hospitalization data is
our inability to determine the diagnostic method. Multiple
diagnostic assays exist for blastomycosis and many have a low
specificity due to cross-reactivity, particularly with histoplasmosis.
Additionally, misdiagnosis may occur with tuberculosis, malig-
nancy [11,39,40] or bacterial community acquired pneumonia
[14,41], among other conditions. However, this has been shown to
differ by region since physicians in areas with higher incidence
may have blastomycosis higher on their list of differential
diagnoses [42]. Additionally, the use of ICD-9-CM code provides
little information regarding clinical diagnostic decisions and ICD-
9-CM codes are primarily used for billing purposes which could
contribute biases [43]. CPT codes were only available for limited
states and years. We extracted these CPT codes for these states but
unfortunately found unreliable coding and were not able to
determine method of diagnosis.
This analysis provides an updated and population-based
overview of the epidemiology of blastomycosis hospitalizations in
the United States using a large dataset with a standard methodology
applied across states. Our results are consistent with the overall
known endemic area of the etiologic agent of blastomycosis and
similar to some state-specific or local area epidemiologic reports of
blastomycosis cases. This study identifies Wisconsin, Illinois,
Tennessee, Kentucky and Arkansas as having the highest blasto-
mycosis hospitalization incidence and an increasing incidence in
Illinois and Kentucky. Improved physician awareness in these states
may improve time to diagnosis and patient outcomes.
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